Skip to main content

Table 3 Major adverse cardiac events and medication therapy

From: Long-term prognosis analysis of PARACHUTE device implantation in patients with ischemic heart failure: a single-center experience of Chinese patients

Major Adverse Cardiac Events
 All-cause mortality n, (%) 1 (16.7%)
 Myocardial infarction n, (%) 1 (16.7%)
 Emergent cardiac or aorta surgery n, (%) 0 (0%)
 Selective cardiac or aorta surgery n, (%) 0 (0%)
 Unplanned interventional therapy n, (%) 3 (50%)
 New or worsening HF 3 (50%)
 Erosion of device through LV 0 (0%)
 Cardiac tamponade 0 (0%)
 Device migration 0 (0%)
 Device embolization 1 (0%)
 Peripheral embolization/stroke 0 (0%)
Medication Therapy
 DAPT n, (%) 6 (100%)
 Statin n, (%) 6 (100%)
 Warfarin n, (%) 6 (100%)
 β-Blocker n, (%) 6 (100%)
 ACEI/ARB n, (%) 5 (83.3%)
 Spironolactone n, (%) 5 (83.3%)
  1. Abbreviations: ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin receptor blocker;